The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Epclusa (sofosbuvir and velpatasvir)

What types of adverse reactions were reported when taking Epclusa?

In the clinical studies the most common adverse reactions when taking Epclusa were fatigue and headache. The most common adverse effect when Epclusa was used in combination with ribavirin were fatigue, anemia, nausea, headache, insomnia and diarrhea.

Although less common than the adverse reactions reported above, for some clinical study subjects taking Epclusa they reported mild to moderate rashes and mild to moderate depression. Mild to moderate rashes were also a less common reaction for subjects taking Epclusa with ribavirin.

 

Last Updated: October 2016

 

 

"Co-pay Coupon | EPCLUSA®." Gilead.com. Gilead Sciences, Inc., https://www.epclusainfo.com/co-pay-coupon-registration. Retrieved June 29, 2016

"Highlights of Prescribing Information." FDA.gov. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf. Retrieved June 29, 2016.

"Support Path Harvoni® and Epclusa® Tablets Treatment Support." Gilead.com. Gilead Sciences, Inc., http://www.mysupportpath.com/. Retrieved June 29, 2016.

"U.S. Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C. Gilead.com". http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&. Retrieved June 29, 2016.